Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Geneva, Switzerland and Boston, MA - 31 May 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder, Tim ADAMS, CFO, and Mario CORSO, Senior Director Investor Relations will attend the Jefferies Healthcare Conference. Management will be presenting on Thursday June 8th at 08:30 a.m. and will be hosting one-on-one meetings at the Grand Hyatt Hotel in New York City.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
Company Contact:
CEO Office contact
Delphine Renaud
[email protected]
+41 22 552 1550
Investor Contact
Mario Corso
Senior Director, Investor Relations
[email protected]
781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/70181aa5-664e-4bd9-a30f-7dcaa32de878
